Angiogenesis is an essential process in normal development and in adult physiology, but
can be disrupted in numerous diseases. The concept of targeting angiogenesis for treating …

Four decades ago, angiogenesis was recognized as a therapeutic target for blocking cancer
growth. Because of its importance, VEGF has been at the center stage of antiangiogenic …

Angiogenesis has a causal role in many diseases, including neovascular age-related
macular degeneration (AMD). Identification of key regulators of angiogenesis, including …

The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both
normal and pathological angiogenesis, has revealed innovative therapeutic approaches in …

Vascular endothelial growth factor (VEGF) plays an important role in both physiologic and
pathologic angiogenesis and contributes to increased permeability across both the blood …

Roughly ten years ago the FDA approved most of the presently used anti-VEGF drugs for the
treatment of neovascular AMD and other eye pathologies characterized by ocular …

With the identification of vascular endothelial growth factor (VEGF) and the confirmation of its
pathophysiologic link to retinal and choroidal angiogenesis, numerous agents have been …

Angiogenesis is a critical step in the progression of almost all human malignancies and
some other life-threatening diseases. Anti-angiogenic therapy is a novel and effective …

Vascular endothelial growth factor (VEGF) is a central regulator of both physiological and
pathological angiogenesis. Pegaptanib, a 28‐nucleotide RNA aptamer specific for the …

MOLECULAR MEDICINE OFFERS PROMISE FOR THE prevention of vision loss caused by
ocular neo-vascularization in diabetic retinopathy and exudative age-related macular …